NCT06440174 Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)
| NCT ID | NCT06440174 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Southampton NHS Foundation Trust |
| Condition | Oesophageal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-06-27 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2024-06-27 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational trial that will look at patients undergoing endoscopic ultrasound (EUS) in patients with oesophageal cancer and to determine the proportion of cases in which EUS changes disease management in these patients.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 16 or above with first diagnosis of biopsy-confirmed oesophageal cancer. 2. Referred for EUS examination as part of standard of care investigations. 3. Tumour location in the oesophagus, or gastro-oesophageal junction (Siewert types I-III) 4. MDT decision that patient is potentially curable with radical treatment (e.g., endoscopic treatment, surgery +/- neoadjuvant therapy, or definitive chemoradiotherapy) 5. Prior staging with CT and PET-CT 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 7. Clinical staging of T1-T4, N0-N3, M0 disease 8. Adenocarcinoma or squamous cell carcinoma (SCC) histopathological cell type Exclusion Criteria: 9. Recurrent or residual disease 10. Distant metastatic disease detected before EUS. 11. Previous oesophagectomy or oesophageal radiotherapy 12. Unable to undergo EUS examination. 13. Concurrent malignancy e.g., second primary tumour 14. Other histopathological cell type
Contact & Investigator
Kieran Foley
PRINCIPAL INVESTIGATOR
Chief Investigator, based at Velindre University NHS Trust
Frequently Asked Questions
Who can join the NCT06440174 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Oesophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06440174 currently recruiting?
Yes, NCT06440174 is actively recruiting participants. Contact the research team at value@soton.ac.uk for enrollment information.
Where is the NCT06440174 trial being conducted?
This trial is being conducted at Abercynon, United Kingdom, Bournemouth, United Kingdom, Cambridge, United Kingdom, Cardiff, United Kingdom and 10 additional locations.
Who is sponsoring the NCT06440174 clinical trial?
NCT06440174 is sponsored by University Hospital Southampton NHS Foundation Trust. The principal investigator is Kieran Foley at Chief Investigator, based at Velindre University NHS Trust. The trial plans to enroll 160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.